Q2 2025 Earnings Forecast for AstraZeneca PLC (NASDAQ:AZN) Issued By Zacks Research

AstraZeneca PLC (NASDAQ:AZN) – Zacks Research reduced their Q2 2025 earnings estimates for AstraZeneca in a research note issued on Wednesday, April 17th. Zacks Research analyst R. Department now expects that the company will earn $1.14 per share for the quarter, down from their previous forecast of $1.15. The consensus estimate for AstraZeneca’s current full-year earnings is $4.02 per share. Zacks Research also issued estimates for AstraZeneca’s Q3 2025 earnings at $1.17 EPS, Q4 2025 earnings at $1.25 EPS, FY2025 earnings at $4.63 EPS, Q1 2026 earnings at $1.20 EPS and FY2026 earnings at $5.09 EPS.

A number of other research analysts have also recently commented on AZN. Morgan Stanley initiated coverage on shares of AstraZeneca in a report on Tuesday, January 23rd. They issued an “overweight” rating for the company. Jefferies Financial Group cut shares of AstraZeneca from a “buy” rating to a “hold” rating in a report on Wednesday, January 3rd. Finally, Deutsche Bank Aktiengesellschaft raised shares of AstraZeneca from a “sell” rating to a “hold” rating in a report on Tuesday. Three analysts have rated the stock with a hold rating, three have given a buy rating and one has assigned a strong buy rating to the stock. Based on data from MarketBeat.com, AstraZeneca presently has a consensus rating of “Moderate Buy” and an average target price of $80.00.

AstraZeneca Stock Up 0.4 %

AZN stock opened at $68.53 on Thursday. The stock has a market capitalization of $212.47 billion, a P/E ratio of 35.69, a price-to-earnings-growth ratio of 1.25 and a beta of 0.50. The company has a current ratio of 0.82, a quick ratio of 0.64 and a debt-to-equity ratio of 0.57. AstraZeneca has a 12 month low of $60.47 and a 12 month high of $76.56. The firm has a 50-day moving average price of $66.02 and a 200-day moving average price of $65.85.

AstraZeneca (NASDAQ:AZN) last posted its quarterly earnings data on Thursday, February 8th. The company reported $0.73 earnings per share for the quarter, missing the consensus estimate of $0.74 by ($0.01). AstraZeneca had a return on equity of 30.19% and a net margin of 13.00%. The firm had revenue of $12.02 billion for the quarter, compared to the consensus estimate of $12.07 billion. During the same period in the prior year, the company earned $0.69 EPS. The company’s revenue for the quarter was up 7.3% compared to the same quarter last year.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently made changes to their positions in the company. Beaird Harris Wealth Management LLC lifted its stake in AstraZeneca by 8.9% during the 4th quarter. Beaird Harris Wealth Management LLC now owns 1,851 shares of the company’s stock valued at $125,000 after acquiring an additional 151 shares in the last quarter. First Affirmative Financial Network lifted its stake in AstraZeneca by 2.9% during the 3rd quarter. First Affirmative Financial Network now owns 5,495 shares of the company’s stock valued at $372,000 after acquiring an additional 155 shares in the last quarter. Clearstead Advisors LLC lifted its stake in AstraZeneca by 15.5% during the 3rd quarter. Clearstead Advisors LLC now owns 1,209 shares of the company’s stock valued at $82,000 after acquiring an additional 162 shares in the last quarter. Bryn Mawr Capital Management LLC lifted its stake in AstraZeneca by 0.3% during the 4th quarter. Bryn Mawr Capital Management LLC now owns 61,866 shares of the company’s stock valued at $4,167,000 after acquiring an additional 164 shares in the last quarter. Finally, Center for Financial Planning Inc. lifted its stake in AstraZeneca by 32.9% during the 3rd quarter. Center for Financial Planning Inc. now owns 671 shares of the company’s stock valued at $45,000 after acquiring an additional 166 shares in the last quarter. Institutional investors and hedge funds own 20.35% of the company’s stock.

AstraZeneca Increases Dividend

The company also recently disclosed a Semi-Annual dividend, which was paid on Monday, March 25th. Stockholders of record on Friday, February 23rd were paid a $0.965 dividend. The ex-dividend date of this dividend was Thursday, February 22nd. This represents a dividend yield of 2.3%. This is an increase from AstraZeneca’s previous Semi-Annual dividend of $0.47. AstraZeneca’s dividend payout ratio is currently 100.52%.

AstraZeneca Company Profile

AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. The company's marketed products include Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Truqap, Zoladex, Faslodex, Farxiga, Brilinta, Lokelma, Roxadustat, Andexxa, Crestor, Seloken, Onglyza, Bydureon, Fasenra, Breztri, Symbicort, Saphnelo, Tezspire, Pulmicort, Bevespi, and Daliresp for cardiovascular, renal, metabolism, and oncology.